AU2017357785A1 - Methods and compositions for treatment of cartilage damage and arthritis - Google Patents

Methods and compositions for treatment of cartilage damage and arthritis Download PDF

Info

Publication number
AU2017357785A1
AU2017357785A1 AU2017357785A AU2017357785A AU2017357785A1 AU 2017357785 A1 AU2017357785 A1 AU 2017357785A1 AU 2017357785 A AU2017357785 A AU 2017357785A AU 2017357785 A AU2017357785 A AU 2017357785A AU 2017357785 A1 AU2017357785 A1 AU 2017357785A1
Authority
AU
Australia
Prior art keywords
polypeptide
composition
amino acid
seq
intra
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2017357785A
Other languages
English (en)
Other versions
AU2017357785A2 (en
Inventor
Jorg Goldhahn
Kristen Johnson
Celeste SCOTTI
Igor Vostiar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2017357785A1 publication Critical patent/AU2017357785A1/en
Publication of AU2017357785A2 publication Critical patent/AU2017357785A2/en
Priority to AU2020281098A priority Critical patent/AU2020281098B2/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2017357785A 2016-11-14 2017-11-13 Methods and compositions for treatment of cartilage damage and arthritis Abandoned AU2017357785A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2020281098A AU2020281098B2 (en) 2016-11-14 2020-12-03 Methods and compositions for treatment of cartilage damage and arthritis

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662421534P 2016-11-14 2016-11-14
US62/421,534 2016-11-14
US201762560301P 2017-09-19 2017-09-19
US62/560,301 2017-09-19
PCT/IB2017/057081 WO2018087727A1 (en) 2016-11-14 2017-11-13 Methods and compositions for treatment of cartilage damage and arthritis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2020281098A Division AU2020281098B2 (en) 2016-11-14 2020-12-03 Methods and compositions for treatment of cartilage damage and arthritis

Publications (2)

Publication Number Publication Date
AU2017357785A1 true AU2017357785A1 (en) 2019-04-11
AU2017357785A2 AU2017357785A2 (en) 2019-05-02

Family

ID=60629753

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2017357785A Abandoned AU2017357785A1 (en) 2016-11-14 2017-11-13 Methods and compositions for treatment of cartilage damage and arthritis
AU2020281098A Active AU2020281098B2 (en) 2016-11-14 2020-12-03 Methods and compositions for treatment of cartilage damage and arthritis

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2020281098A Active AU2020281098B2 (en) 2016-11-14 2020-12-03 Methods and compositions for treatment of cartilage damage and arthritis

Country Status (10)

Country Link
US (3) US11351223B2 (enExample)
EP (1) EP3538127A1 (enExample)
JP (2) JP2019535707A (enExample)
KR (2) KR20190084287A (enExample)
CN (2) CN109963579A (enExample)
AU (2) AU2017357785A1 (enExample)
CA (1) CA3043667A1 (enExample)
IL (1) IL266361B2 (enExample)
MX (2) MX2019005621A (enExample)
WO (1) WO2018087727A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117355323A (zh) 2021-05-24 2024-01-05 诺华股份有限公司 用于治疗骨关节炎的方法
TW202306970A (zh) 2021-05-24 2023-02-16 瑞士商諾華公司 用於治療骨關節炎之方法
EP4430395A1 (en) * 2021-11-10 2024-09-18 Novartis AG Methods for determining the biological activity of angptl polypeptides

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1490483B1 (en) 2001-04-19 2015-06-03 The Scripps Research Institute In vivo incorporation of unnatural amino acids
DK1578949T3 (da) 2002-10-16 2009-07-27 Scripps Research Inst Stedspecifik optagelse af keto-aminnosyrer hos proteiner
KR20050073559A (ko) 2002-10-16 2005-07-14 더 스크립스 리서치 인스티튜트 당단백질 합성
CN103289960B (zh) 2003-04-17 2017-04-26 斯克利普斯研究院 扩展真核生物遗传密码
WO2005007624A2 (en) 2003-07-07 2005-01-27 The Scripps Research Institute Compositions of orthogonal glutamyl-trna and aminoacyl trna synthetase pairs and uses thereof
WO2005007870A2 (en) 2003-07-07 2005-01-27 The Scripps Research Institute COMPOSITIONS OF ORTHOGONAL LEUCYL-tRNA AND AMINOACYL-tRNA SYNTHETASE PAIRS AND USES THEREOF
DE602004011789T2 (de) 2003-07-07 2009-02-12 The Scripps Research Institute, La Jolla Zusammensetzungen der orthogonalen Lysyl-tRNA und Aminoacyl-tRNA Synthetase Paaren und ihre Verwendungen
EP1794323B1 (en) 2004-09-21 2014-08-06 The Scripps Research Institute In vivo incorporation of alkynyl amino acids into proteins in eubacteria
AU2005330514B2 (en) 2004-10-27 2011-05-12 The Scripps Research Institute Orthogonal translation components for the in vivo incorporation of unnatural amino acids
CA2638763A1 (en) 2006-03-09 2007-09-13 The Scripps Research Institute System for the expression of orthogonal translation components in eubacterial host cells
EP2118150B1 (en) 2007-02-14 2015-09-23 Biocompatibles UK Limited Derivatisation of biological molecules
CN102307902B (zh) * 2008-12-10 2016-02-24 埃博灵克斯股份有限公司 用于治疗与血管发生相关的疾病和病症的针对血管生成素/Tie系统的氨基酸序列和包括其的多肽
PE20160507A1 (es) * 2009-07-14 2016-05-20 Scripps Research Inst Diferenciacion de celulas madre mesenquimales
UY32979A (es) * 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
AU2013204754C1 (en) * 2012-05-16 2018-10-11 Takeda Pharmaceutical Company Limited Nucleophilic Catalysts for Oxime Linkage
US9301971B2 (en) * 2013-03-08 2016-04-05 Novartis Ag Peptides and compositions for treatment of joint damage
UY35368A (es) * 2013-03-08 2014-10-31 Irm Llc Péptidos y composiciones para el tratamiento de daño articular
WO2014151953A1 (en) * 2013-03-15 2014-09-25 The California Institute For Biomedical Research Compounds and methods for inducing chondrogenesis
UY36118A (es) * 2014-05-13 2016-01-08 Novartis Ag Compuestos y composiciones para inducir condrogénesis

Also Published As

Publication number Publication date
RU2019117884A (ru) 2020-12-14
EP3538127A1 (en) 2019-09-18
US11351223B2 (en) 2022-06-07
CA3043667A1 (en) 2018-05-17
KR20190084287A (ko) 2019-07-16
MX2019005621A (es) 2019-08-12
US20190269754A1 (en) 2019-09-05
IL266361A (en) 2019-06-30
KR20240045351A (ko) 2024-04-05
MX2022011897A (es) 2022-10-18
IL266361B1 (en) 2023-10-01
CN109963579A (zh) 2019-07-02
US20250302915A1 (en) 2025-10-02
AU2020281098A1 (en) 2021-01-14
WO2018087727A1 (en) 2018-05-17
US20220331398A1 (en) 2022-10-20
AU2020281098B2 (en) 2024-05-02
JP2019535707A (ja) 2019-12-12
RU2019117884A3 (enExample) 2021-02-05
AU2017357785A2 (en) 2019-05-02
CN117860868A (zh) 2024-04-12
IL266361B2 (en) 2024-02-01
JP2023039962A (ja) 2023-03-22

Similar Documents

Publication Publication Date Title
US10328126B2 (en) Peptides and compositions for treatment of joint damage
US20250302915A1 (en) Methods and compositions for treatment of cartilage damage and arthritis
US20220402987A1 (en) Peptides and compositions for treatment of joint damage
RU2777504C2 (ru) Способы и композиции для лечения повреждения хряща и артрита
HK1260928A1 (en) Peptides and compositions for treatment of joint damage
HK1214754B (en) Peptides and compositions for treatment of joint damage

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT FILED 12 APR 2019

MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted